Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Average Recommendation of "Moderate Buy" from Brokerages

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) have received a consensus rating of "Moderate Buy" from the five ratings firms that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $17.25.

Several analysts have commented on the company. JMP Securities restated a "market outperform" rating and issued a $21.00 price target on shares of Enanta Pharmaceuticals in a report on Tuesday, February 11th. HC Wainwright reiterated a "buy" rating and issued a $18.00 price target on shares of Enanta Pharmaceuticals in a report on Tuesday, February 11th. Finally, StockNews.com raised Enanta Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Wednesday, February 19th.

View Our Latest Analysis on ENTA

Insider Activity

In related news, CEO Jay R. Luly bought 45,000 shares of the company's stock in a transaction that occurred on Wednesday, February 12th. The shares were acquired at an average cost of $5.69 per share, for a total transaction of $256,050.00. Following the acquisition, the chief executive officer now owns 846,638 shares in the company, valued at $4,817,370.22. This represents a 5.61 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 13.89% of the company's stock.

Institutional Investors Weigh In On Enanta Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the company. Krensavage Asset Management LLC grew its stake in shares of Enanta Pharmaceuticals by 19.7% during the third quarter. Krensavage Asset Management LLC now owns 1,498,074 shares of the biotechnology company's stock valued at $15,520,000 after acquiring an additional 246,736 shares in the last quarter. RA Capital Management L.P. purchased a new stake in Enanta Pharmaceuticals during the 4th quarter worth approximately $5,968,000. Marshall Wace LLP raised its position in shares of Enanta Pharmaceuticals by 9.3% in the 4th quarter. Marshall Wace LLP now owns 930,087 shares of the biotechnology company's stock valued at $5,348,000 after purchasing an additional 79,197 shares in the last quarter. Millennium Management LLC boosted its stake in shares of Enanta Pharmaceuticals by 22.7% during the 4th quarter. Millennium Management LLC now owns 896,987 shares of the biotechnology company's stock valued at $5,158,000 after buying an additional 165,692 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in shares of Enanta Pharmaceuticals by 3.1% during the third quarter. Geode Capital Management LLC now owns 477,351 shares of the biotechnology company's stock worth $4,946,000 after buying an additional 14,575 shares in the last quarter. 94.99% of the stock is owned by institutional investors and hedge funds.

Enanta Pharmaceuticals Stock Performance

Shares of NASDAQ ENTA opened at $4.73 on Friday. The firm has a market cap of $100.91 million, a P/E ratio of -0.96 and a beta of 0.47. Enanta Pharmaceuticals has a 1 year low of $4.52 and a 1 year high of $17.24. The firm's 50 day moving average price is $6.39 and its 200 day moving average price is $8.00.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last posted its quarterly earnings data on Monday, February 10th. The biotechnology company reported ($1.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative return on equity of 75.53% and a negative net margin of 157.57%. As a group, equities analysts predict that Enanta Pharmaceuticals will post -4.65 EPS for the current year.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.

Featured Stories

• Five stocks we like better than Enanta Pharmaceuticals
• Quiet Period Expirations Explained
• Archer Aviation’s Africa Deal Could Boost ACHR Stock
• Natural Gas Prices Continue To Rally, These Stocks Should Benefit
• Are Short Sellers Wrong About These 3 Semiconductor Stocks?
• The 3 Best Retail Stocks to Shop for in August
• Boeing Gets $50B in March Orders—Is BA Stock a Buy Now?

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Enanta Pharmaceuticals Right Now?

Before you consider Enanta Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enanta Pharmaceuticals wasn't on the list.

While Enanta Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here